GPCM
ARCT icon

Granite Point Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Granite Point Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-100,000
Closed -$4.29M – 153
2020
Q3 		$4.29M Buy
100,000
+50,000
+100% +$2.48M 0.23% 55
2020
Q2 		$2.34M Buy
+50,000
New +$1.72M 0.12% 80
2014
Q4 		– Sell
-2,857
Closed -$309K – 79
2014
Q3 		$309K Sell
2,857
-5,714
-67% -$745K 0.15% 73
2014
Q2 		$1.04M Buy
+8,571
New +$1.03M 0.72% 30

Other funds holding ARCT

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return

Granite Point Capital Management's ARCT Position: Q4 2020 in Review

Granite Point Capital Management sold out of Arcturus Therapeutics (ARCT) in Q4 2020, closing a stake of 100,000 shares — an estimated $4.29M sold.

Granite Point Capital Management first reported a position in ARCT in Q2 2014 and held it in 4 quarters. The position peaked at $4.29M in Q3 2020. 135 funds tracked by Wall St. Rank hold ARCT as of Q4 2020.

  • Granite Point Capital Management reported no remaining Arcturus Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Granite Point Capital Management sold 100,000 Arcturus Therapeutics shares in Q4 2020, an estimated $4.29M.
  • Granite Point Capital Management first reported a position in Arcturus Therapeutics in Q2 2014 and held it in 4 quarters.
  • Granite Point Capital Management's Arcturus Therapeutics position peaked at $4.29M in Q3 2020.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2020.

Based on Granite Point Capital Management's 13F filing for Q4 2020, filed 5 Feb 2021.